Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.

Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, Reimherr F, Miller DD, McGee M, Khan A, Canive JM, Davis SM, Hsiao JK, Lieberman JA; CATIE Investigators.

Schizophr Res. 2008 Mar;100(1-3):39-52. doi: 10.1016/j.schres.2007.11.034. Epub 2008 Jan 11.

PMID:
18191383
2.

Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.

Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, Rosenheck RA, Keefe RS, Miller AL, Belz I, Hsiao JK; CATIE Investigators.

Am J Psychiatry. 2007 Mar;164(3):415-27.

PMID:
17329466
3.

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.

Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK; CATIE Investigators.

Am J Psychiatry. 2006 Apr;163(4):611-22.

PMID:
16585435
4.

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators.

N Engl J Med. 2005 Sep 22;353(12):1209-23. Epub 2005 Sep 19. Erratum in: N Engl J Med. 2010 Sep 9;363(11):1092-3.

5.

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA; CATIE Investigators; Neurocognitive Working Group.

Arch Gen Psychiatry. 2007 Jun;64(6):633-47.

PMID:
17548746
6.

Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia.

Mohamed S, Rosenheck RA, Lin H, Swartz M, McEvoy J, Stroup S.

J Nerv Ment Dis. 2015 Jul;203(7):486-92. doi: 10.1097/NMD.0000000000000317.

PMID:
26075840
7.

Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.

Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA, Reimherr F, McGee MF, Keefe RS, McEvoy JP, Hsiao JK, Lieberman JA; CATIE Investigators.

Am J Psychiatry. 2007 Mar;164(3):428-36.

PMID:
17329467
8.

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.

McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK; CATIE Investigators.

Am J Psychiatry. 2006 Apr;163(4):600-10.

PMID:
16585434
9.

What CATIE found: results from the schizophrenia trial.

Swartz MS, Stroup TS, McEvoy JP, Davis SM, Rosenheck RA, Keefe RS, Hsiao JK, Lieberman JA.

Psychiatr Serv. 2008 May;59(5):500-6. doi: 10.1176/ps.2008.59.5.500.

11.

Effectiveness of switching antipsychotic medications.

Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA.

Am J Psychiatry. 2006 Dec;163(12):2090-5.

PMID:
17151159
12.

Olanzapine versus other atypical antipsychotics for schizophrenia.

Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, Kissling W, Leucht S.

Cochrane Database Syst Rev. 2010 Mar 17;(3):CD006654. doi: 10.1002/14651858.CD006654.pub2. Review.

13.

Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia.

Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J.

BMC Psychiatry. 2006 Feb 21;6:8.

14.

Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.

Dossenbach M, Pecenak J, Szulc A, Irimia V, Anders M, Logozar-Perkovic D, Peciukaitiene D, Kotler M, Smulevich AB, West TM, Lowry AJ, Treuer T.

J Clin Psychiatry. 2008 Dec;69(12):1901-15. Epub 2008 Sep 9.

PMID:
19012820
15.

Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia.

Addington DE, Mohamed S, Rosenheck RA, Davis SM, Stroup TS, McEvoy JP, Swartz MS, Lieberman JA.

J Clin Psychiatry. 2011 Jan;72(1):75-80. doi: 10.4088/JCP.09m05258gre. Epub 2010 Sep 21.

16.

Ziprasidone versus other atypical antipsychotics for schizophrenia.

Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, Bhoopathi PS, Kissling W, Leucht S.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD006627. doi: 10.1002/14651858.CD006627.pub2. Review.

17.

How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.

Suzuki T, Uchida H, Watanabe K, Nomura K, Takeuchi H, Tomita M, Tsunoda K, Nio S, Den R, Manki H, Tanabe A, Yagi G, Kashima H.

Psychopharmacology (Berl). 2007 Dec;195(2):285-95. Epub 2007 Aug 14.

PMID:
17701027
18.

Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials.

Stauffer V, Ascher-Svanum H, Liu L, Ball T, Conley R.

BMC Psychiatry. 2009 Mar 31;9:13. doi: 10.1186/1471-244X-9-13.

19.

One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis.

San L, Arranz B, Perez V, Safont G, Corripio I, Ramirez N, Dueñas R, Alvarez E.

Psychiatry Res. 2012 Dec 30;200(2-3):693-701. doi: 10.1016/j.psychres.2012.07.005. Epub 2012 Sep 3.

PMID:
22954905
20.

Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.

Dossenbach M, Arango-Dávila C, Silva Ibarra H, Landa E, Aguilar J, Caro O, Leadbetter J, Assunção S.

J Clin Psychiatry. 2005 Aug;66(8):1021-30.

PMID:
16086618

Supplemental Content

Support Center